Accurately predicting protein-ligand binding free energies (BFEs) remains a central challenge in drug discovery, particularly because the most reliable methods, such as free energy perturbation (FEP), are computationally intensive and difficult to scale. Here, we introduce a hybrid quantum-classical framework that combines Mining Minima sampling with quantum mechanically refined ligand partial charges, QM/MM interaction evaluation, and variational quantum eigensolver (VQE)-based electronic energy correction. This design enables explicit treatment of polarization, charge redistribution, and electronic correlation effects that are often underestimated in purely classical scoring schemes, while retaining computational efficiency. Across 23 protein targets and 543 ligands, the method achieves a mean absolute error of about 1.10 kcal/mol with strong rank-order fidelity (Pearson R = 0.75, Spearman rho = 0.76, Kendall tau = 0.57), consistent with the performance of contemporary FEP protocols. Notably, the workflow requires only about 25 minutes per ligand on standard compute resources, resulting in an approximate 20-fold reduction in computational cost relative to alchemical free energy approaches. This level of accuracy and efficiency makes the method well-suited for high-throughput lead optimization and iterative design cycles in pharmaceutical discovery. The framework also provides a natural foundation for future integration with machine learning models to enable predictive, large-scale, and adaptive screening strategies.
Accurately predicting protein-ligand binding free energies (BFEs) remains a central challenge in drug discovery, particularly because the most reliable methods, such as free energy perturbation (FEP), are computationally intensive and difficult to scale. Here, we introduce a hybrid quantum-classical framework that combines Mining Minima sampling with quantum mechanically refined ligand partial charges, QM/MM interaction evaluation, and variational quantum eigensolver (VQE)-based electronic energy correction. This design enables explicit treatment of polarization, charge redistribution, and electronic correlation effects that are often underestimated in purely classical scoring schemes, while retaining computational efficiency. Across 23 protein targets and 543 ligands, the method achieves a mean absolute error of about 1.10 kcal/mol with strong rank-order fidelity (Pearson R = 0.75, Spearman rho = 0.76, Kendall tau = 0.57), consistent with the performance of contemporary FEP protocols. Notably, the workflow requires only about 25 minutes per ligand on standard compute resources, resulting in an approximate 20-fold reduction in computational cost relative to alchemical free energy approaches. This level of accuracy and efficiency makes the method well-suited for high-throughput lead optimization and iterative design cycles in pharmaceutical discovery. The framework also provides a natural foundation for future integration with machine learning models to enable predictive, large-scale, and adaptive screening strategies.
• A study published on arXiv presents a hybrid framework combining VQE, QM/MM, and statistical thermodynamics to predict protein-ligand binding free energies (BFEs) accurately and rapidly. • Explicitly handles polarization, charge redistribution, and electron correlation—often missed by purely classical methods—achieving an outstanding mean absolute error (MAE) of 1.10 kcal/mol. • Reduces computational costs 20-fold compared to conventional alchemical free energy perturbation (FEP) approaches (taking approximately 25 minutes per ligand), establishing a robust foundation for high-throughput lead optimization and future ML-integrated screening. [Quantum Biology Society] Predicting protein-ligand binding free energy (BFE), a core challenge in drug discovery, has long faced a dilemma: increasing accuracy requires massive amounts of computing resources. Traditional high-precision techniques, such as free energy perturbation (FEP), are computationally intensive and difficult to scale for large-scale applications. Recently, a groundbreaking study has been published that breaks through these limitations using a hybrid quantum-classical algorithm based on a variational quantum eigensolver (VQE), reducing computational costs by 20-fold and drawing intense interest from the pharmaceutical industry. ■ Perfect Synergy Between Quantum Mechanics and Statistical Thermodynamics The study titled "Synergistic Computational Approaches for Accelerated Drug Discovery: Integrating Quantum Mechanics, Statistical Thermodynamics, and Quantum Computing," released on the preprint repository arXiv, combines the advantages of classical and quantum computing. A research team led by Farzad Molani and Art E. Cho (from inCerebro and Korea University) designed a new framework that maximizes both computational efficiency and precision. The researchers integrated quantum mechanically refined ligand partial charges and QM/MM interaction evaluations based on the Mining Minima sampling technique. Notably, they added an electronic energy correction step using a variational quantum eigensolver (VQE), significantly boosting precision without compromising efficiency. ■ Overcoming the Blind Spots of Polarization and Electron Correlation The greatest strength of this hybrid model is its ability to explicitly handle effects such as polarization, charge redistribution, and electron correlation, which are frequently underestimated in purely classical scoring systems. By applying this system to 23 protein targets and 543 diverse ligands, the team successfully achieved an excellent MAE of 1.10 kcal/mol along with high fidelity in ranking predictions. ■ 20x Faster Computation: A Cornerstone for Machine Learning (ML) Integration The most encouraging achievement is the overwhelming computational speed. Using standard computing resources, the workflow completed calculations in approximately 25 minutes per ligand, representing a 20-fold reduction in costs compared to traditional FEP methods. The researchers emphasized that this level of accuracy and efficiency is highly suitable for the high-throughput lead optimization process in pharmaceutical drug discovery. Furthermore, this framework is expected to provide an excellent basis for realizing large-scale adaptive predictive screening strategies through seamless integration with future machine learning (ML) models.
Accurate prediction of binding affinities and efficient lead optimization remain central challenges in computational drug discovery, particularly for complex biological targets characterized by rugged energy landscapes, conformational heterogeneity, and high-dimensional interaction spaces. Classical computational methods—such as molecular docking, force-field–based simulations, and deep learning models—have made substantial progress, yet they often struggle to capture quantum-mechanical effects and long-range correlations critical to molecular recognition. This study explores a quantum-enhanced framework that integrates Variational Quantum Algorithms (VQAs), quantum-inspired Hamiltonian modeling, and hybrid quantum–classical optimization workflows to improve the fidelity and scalability of drug discovery pipelines. By encoding molecular interactions into parameterized quantum circuits, the framework leverages quantum superposition and entanglement to explore complex chemical space more efficiently, enabling refined estimation of binding energies and accelerated identification of high-quality leads. Preliminary simulations indicate that VQA-based estimators outperform classical baselines for challenging protein–ligand systems, reducing prediction error while maintaining computational tractability. These findings highlight the emerging potential of quantum technologies to enable more accurate, data-efficient, and mechanistically grounded drug discovery for next-generation therapeutics.
The exorbitant costs, protracted timelines, and elevated attrition rates associated with traditional drug-discovery pipelines underscore the pressing necessity for computational frameworks that can elucidate biomolecular interactions with quantum-level precision and practical scalability. This study introduces a Hybrid Quantum Classical (HQC) framework that combines quantum variational algorithms, classical molecular dynamics, and quantum-assisted machine-learning optimization into a single drug-screening workflow. It builds on the basic idea of Quantum Molecular Simulation (QMS). In the suggested design, quantum processors are used to selectively fix high-fidelity electronic interactions in reactive binding sites, while classical engines model the large-scale conformational dynamics of biomolecular environments. An adaptive quantum-machine-learning layer speeds up convergence even more by learning how structure and energy are related from quantum-refined descriptors. Benchmark tests against oncogenic targets like EGFR, BCR-ABL1, and p53 show that our method is up to 27% more accurate at converging binding energy and takes 4.3 times less time to compute than standard density-functional-theory and standalone QMS methods. The HQC framework makes quantum drug simulation possible for real-world drug discovery by reducing the limitations of current quantum hardware while keeping electronic-scale accuracy. This study demonstrates that hybrid quantum-classical modeling is a scalable and hardware-compatible approach for advancing next-generation computational drug design and precision therapeutics.
Abstract Quantum computing has emerged as a powerful tool for modeling molecular systems with high accuracy, accelerating the search for novel therapeutic targets. In this study, we present a two-stage hybrid workflow that combines a Quantum Graph Neural Network with a Variational Quantum Eigensolver to identify potent serine neutralizers in the QM9 dataset. In the first stage, an advanced quantum graph neural network architecture incorporating attention layers, self-distillation, and an adaptive learning-rate schedule is trained to predict ionization potentials and binding free energies. Across five independent random-seed trials, our adaptive-thresholded QGNN–VQE pipeline achieves an average R2 R 2 of 0.990±0.008 0.990 ± 0.008 and a mean absolute error of 0.034±0.001 0.034 ± 0.001 eV ( ≈0.79±0.03 ≈ 0.79 ± 0.03 kcal/mol) on the QM9 validation set, demonstrating robust, chemical-accuracy-level predictions. Building on these high-precision predictions, the second stage employs a QAOA-inspired hybrid ranking scheme that merges quantum graph neural network outputs, feature-space similarity (via and cosine similarity), and variational quantum eigensolver-derived energy stability. This α α -weighted ( α=0.95 α = 0.95 ) scoring framework is applied to over 133,000 molecules, efficiently parsed in parallel. The final ranked list is validated through an improved bijection test, featuring an adaptive similarity threshold to ensure both structural and functional robustness. The top-scoring candidate identified by our pipeline is 5,6,7-tetrahydro-4 H-pyrazolo[4,3-c]pyridin-4-one, highlighting the efficacy of quantum-enhanced modeling in pinpointing complex pharmacological targets. These findings underscore the transformative potential of hybrid quantum-classical workflows in drug discovery, offering a flexible blueprint for advanced screening of other critical biomolecular interactions in the rapidly expanding field of quantum biology. GraphicAbstract VQE for Serine Neutralization
The use of free energy perturbation (FEP) methods to study protein-ligand complexes is one of the most important tools in structure-based drug design. Because FEP methods typically rely on force fields, they may suffer from force field parameter-related issues. Herein, we present a quantum mechanics/molecular mechanics (QM/MM) hybrid method to overcome deficiencies in force-field models by using QM bookending approaches on both classical and quantum hardware. In the MM part of this QM/MM FEP method, AMBER is used to simulate the protein receptor and the unperturbed moiety of the ligand, with the ff19SB and GAFF2 force fields. In the QM part, QUICK was used to conduct Hartree-Fock (HF) calculations, followed by heat-bath configuration interaction (HCI) as a benchmark on classical devices. To enable the HCI function in QUICK, we developed a Python-based interface to execute HCI from IBM's qiskit-addon-dice-solver. Moreover, the same interface also enabled this work to execute QM/MM FEP calculations on quantum hardware using the Local Unitary Cluster Jastrow (LUCJ) ansatz, followed by sample-based diagonalization (SQD) and extended-SQD (extSQD) post-processing. Using a series of thermolysis inhibitors as an example, we find reasonable agreement with experiment between the classical HCI method and the LUCJ-SQD/extSQD method, with the latter yielding a result closer to the experimental value. The execution time between the HCI-based FEP method and the LUCJ-SQD/extSQD-based FEP method is also comparable, indicating a high potential for utility in the noisy intermediate-scale quantum (NISQ) era.
The large search space and the challenge of accurately simulating quantum-level molecular interactions are the fundamental causes of the delayed, complicated, and costly process of discovering new medications. The effectiveness of conventional computational techniques, including molecular docking and molecular dynamics, to assess molecular characteristics and provide highly accurate drug candidate predictions is constrained. This paper presents a Quantum-Assisted Drug Discovery Simulation framework that combines cutting-edge quantum computing algorithms, specifically the Quantum Approximate Optimization Algorithm (QAOA) and the Variational Quantum Eigensolver (VQE), with traditional molecular docking tools like RDKit and AutoDock. The system uses these quantum algorithms to perform very accurate Quantum Refinement on the most potential therapeutic protein poses found by classical identification. This hybrid approach seeks to optimize drug-protein interactions more quickly, speed up early-stage drug discovery, and create opportunities for less costly, more accurate medical research, even though a combination of quantum and classical calculations allows more accurate prediction of molecular energies and binding affinities.